Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Blood cancer journal·2026
Same author

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

American journal of hematology·2026
Same author

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

American journal of hematology·2026
Same author

Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis.

American journal of hematology·2026
Same author

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

American journal of hematology·2026
Same author

Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia.

Leukemia & lymphoma·2025

Related Experiment Video

Updated: Dec 20, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.0K

Optimizing patient selection for treatment-free remission.

Caitlin R Rausch1, Shilpa Paul1

  • 1Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|May 22, 2020
PubMed
Summary

Treatment-free remission is a new goal for chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitors. Selecting the right patients for stopping nilotinib treatment requires careful consideration of individual factors.

Keywords:
BCR–ABL1Chronic myeloid leukemiatreatment-free remissiontyrosine kinase inhibitors

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.4K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.2K

Related Experiment Videos

Last Updated: Dec 20, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.0K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.4K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.2K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) treatment, significantly improving patient survival.
  • Continuous TKI therapy is crucial for optimal outcomes but can affect quality of life.
  • Deep molecular response enables exploration of treatment-free remission (TFR) in CML.

Observation:

  • Nilotinib is the only FDA-approved TKI for treatment-free remission in CML.
  • Patient and disease characteristics are critical for TFR candidacy.
  • Various TKIs have shown heterogeneous data regarding TFR.

Findings:

  • The decision to attempt TFR involves a complex interplay of patient-specific and disease-related factors.
  • Identifying optimal candidates for TFR is essential for successful treatment discontinuation.
  • Continuous monitoring is necessary for patients attempting TFR.

Implications:

  • Treatment-free remission offers a potential pathway to improved quality of life for CML patients.
  • Understanding TFR candidacy criteria is vital for clinicians and patients.
  • Further research is needed to optimize TFR strategies across different TKIs.